Filter
184
Filtered Results: 184
Text search:
delamanid
Featured
Recommendations
30
New Publications
40
Language
Document type
No document type
96
Guidelines
36
Studies & Reports
21
Manuals
14
Training Material
6
Strategic & Response Plan
4
Fact sheets
3
Situation Updates
2
Brochures
1
Infographics
1
Countries / Regions
Western and Central Europe
15
Eastern Europe
11
South Africa
6
Argentina
5
Global
4
Latin America and the Carribbean
4
Germany
4
Bolivia
3
India
3
Nigeria
2
Malawi
2
Asia
2
South–East Asia Region
2
Eastern Europe and Central Asia
2
Russia
2
Ethiopia
2
Tajikistan
1
Switzerland
1
Colombia
1
Ukraine
1
Turkey
1
Estonia
1
Burkina Faso
1
Peru
1
Guinea
1
Guinea-Bissau
1
Venezuela
1
Congo, Democratic Republic of
1
West and Central Africa
1
Paraguay
1
East and Southern Africa
1
Brazil
1
Namibia
1
Romania
1
Georgia
1
Central African Republic
1
Chad
1
Botswana
1
Zambia
1
Authors & Publishers
Publication Years
Category
Clinical Guidelines
42
Countries
40
Public Health
5
Key Resources
3
Pharmacy & Technologies
3
Women & Child Health
2
Toolboxes
TB
122
COVID-19
10
HIV
9
Caregiver
9
Pharmacy
6
Mental Health
3
Refugee
3
Global Health Education
3
AMR
3
Ebola & Marburg
2
NTDs
2
Conflict
2
Rapid Response
1
Disability
1
Social Ethics
1
Planetary Health
1
Health Financing Toolbox
1
Polio
1
Following review of the latest evidence, WHO recommends that TB-LAMP can be used as a replacement for microscopy for the diagnosis of pulmonary TB in adults with signs and symptoms of TB. It can also be considered as a follow-on test to microscopy in adults with signs and symptoms of pulmonary TB, e...
HIV & AIDS Treatment in Practice No. 198
A practical tool to help health workers in the clinical and operational management of multidrug-resistant tuberculosis with special focus on the introduction, implementation and management of the nine-month treatment regimen.
Report of the 23rd WHO Expert Committee on the selection and use of essential medicines
This executive summary reports the recommendations made by the Expert Committee for the 2021 update of the WHO Model List of Essential Medicines (EML) and the Model List of Essential Medicine for Children (EMLc)...
Цей документ описує кроки, необхідні для визначення скоригованого інтервалу QT (QTc) в
ході моніторингу ЕКГ пацієнтів, які отримують препарати для лікування ХР ТБ, що...
Este documento presenta modelos de algoritmos que permiten investigar por métodos bacteriológicos a los pacientes para el diagnóstico de tuberculosis (TB), TB asociada al Virus de Inmunodeficiencia Humana (TB-HIV) y TB drogorresistente (TBDR).
A review of prospects for existing antibiotics ad new therapeutics
Assurer des prestations optimales dans la chaîne de soins destinés aux patients tuberculeux
Deuxième édition - Juin 2018
Eine Leitlinie zur Diagnostik und Therapie, einschließlich Chemoprävention und -prophylaxe des Deutschen Zentralkomitees zur Bekämpfung der Tuberkulose e.V. im Auftrag der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.
Tuberculosis Guideline for Adults
Guideline for Diagnosis...
Meeting Report 27-29 October 2020
The overall goal of the meeting was to discuss recent changes in treatment regimens and diagnostics for drug-resistant TB and to determine how these impact on the definition of XDR-TB, with a view to revising this definition. The pre-existing definition of XDR-TB w...
This report presents an overview of the transition process in Azerbaijan, some sustainability aspects and challenges stemming from donor withdrawal from TB-related activities, along with recommendations on how to overcome transition-related difficulties and ensure sustainability.
6 July 2021. Three new nucleic acid amplification test (NAAT) classes are endorsed by WHO and included.
The latest operational handbook includes the new classes recommended by WHO. It aims at facilitating the implementation of the WHO recommendations by the Member States, technical partners, and ot...
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.
